These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. HIV-1 neutralization: mechanisms and relevance to vaccine design. Zwick MB; Burton DR Curr HIV Res; 2007 Nov; 5(6):608-24. PubMed ID: 18045117 [TBL] [Abstract][Full Text] [Related]
7. Vaccine to prevent AIDS overstated. Lewis D Res Initiat Treat Action; 1999 Jan; 5(1):11-2. PubMed ID: 11366223 [TBL] [Abstract][Full Text] [Related]
8. Antibody epitope exposure and neutralization of HIV-1. Pantophlet R Curr Pharm Des; 2010; 16(33):3729-43. PubMed ID: 21128886 [TBL] [Abstract][Full Text] [Related]
9. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Emini EA; Koff WC Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131 [No Abstract] [Full Text] [Related]
10. Immunology. Close to the edge: neutralizing the HIV-1 envelope. Nabel GJ Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295 [No Abstract] [Full Text] [Related]
11. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Pinter A Curr HIV Res; 2007 Nov; 5(6):542-53. PubMed ID: 18045110 [TBL] [Abstract][Full Text] [Related]
12. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. Gilbert PB; Peterson ML; Follmann D; Hudgens MG; Francis DP; Gurwith M; Heyward WL; Jobes DV; Popovic V; Self SG; Sinangil F; Burke D; Berman PW J Infect Dis; 2005 Mar; 191(5):666-77. PubMed ID: 15688279 [TBL] [Abstract][Full Text] [Related]
13. Structure-based vaccine design in HIV: blind men and the elephant? Pejchal R; Wilson IA Curr Pharm Des; 2010; 16(33):3744-53. PubMed ID: 21128885 [TBL] [Abstract][Full Text] [Related]
14. AIDS research. Novel antibody response may explain HIV vaccine success. Cohen J Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167 [No Abstract] [Full Text] [Related]
15. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
16. Virology. HIV may shed some protection as it jumps to new hosts. Cohen J Science; 2004 Mar; 303(5666):1956. PubMed ID: 15044774 [No Abstract] [Full Text] [Related]
17. Back to the future: covalent epitope-based HIV vaccine development. Paul S; Planque S; Nishiyama Y; Escobar M; Hanson C Expert Rev Vaccines; 2010 Sep; 9(9):1027-43. PubMed ID: 20822346 [TBL] [Abstract][Full Text] [Related]
18. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Haynes BF; Montefiori DC Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the exposure of induced HIV glycoprotein epitopes in a potential HIV pseudovirion vaccine. Devitt G; Emerson V; Pisch T; Keppler OT; Bosch V Vaccine; 2007 Mar; 25(12):2161-7. PubMed ID: 17241712 [TBL] [Abstract][Full Text] [Related]
20. Antibody recognition of a carbohydrate epitope: a template for HIV vaccine design. Scanlan C; Calarese D; Lee HK; Blixt O; Wong CH; Wilson I; Burton D; Dwek R; Rudd P Adv Exp Med Biol; 2005; 564():7-8. PubMed ID: 16400800 [No Abstract] [Full Text] [Related] [Next] [New Search]